Fiduciary Planning’s iShares Biotechnology ETF IBB Stock Holding History

Fiduciary Planning’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3	Closed	–	–	271
2020 Q4	$0	Hold	3	–	–	﹤0.01%	249
2020 Q3	$0	Buy	+3	New	+$407	﹤0.01%	200

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fiduciary Planning's IBB Position: Q1 2021 in Review

Fiduciary Planning sold out of iShares Biotechnology ETF (IBB) in Q1 2021, closing a stake of 3 shares.

Fiduciary Planning first reported a position in IBB in Q3 2020 and held it in 2 quarters. The position peaked at $0 in Q4 2020. 845 funds tracked by Wall St. Rank hold IBB as of Q1 2021.

Fiduciary Planning reported no remaining iShares Biotechnology ETF position as of Q1 2021 after selling out during the quarter.
Fiduciary Planning sold 3 iShares Biotechnology ETF shares in Q1 2021.
Fiduciary Planning first reported a position in iShares Biotechnology ETF in Q3 2020 and held it in 2 quarters.
Fiduciary Planning's iShares Biotechnology ETF position peaked at $0 in Q4 2020.
845 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2021.

Based on Fiduciary Planning's 13F filing for Q1 2021, filed 20 May 2021.